Frost & Sullivan Awards ChromaDex With Most Promising Ingredient of the Year Award
IRVINE, Calif., March 11, 2011 /PRNewswire/ – ChromaDex Corporation (OTC Bulletin Board: CDXC), announced today that the Company has been awarded the 2010 North American Health Ingredients Most Promising Ingredient of the Year award by the independent research company, Frost & Sullivan, for its proprietary branded ingredient pTeroPure(TM) Pterostilbene.
“We are extremely pleased that Frost & Sullivan has recognized the potential of pTeroPure in the marketplace,” said Frank Jaksch, ChromaDex CEO. “The award confirms pTeroPure’s ability to produce sustained value across multiple market channels by providing distinct, science-based health benefits to a broad range of consumer segments. Furthermore, it validates our corporate strategy of continuing to develop and commercialize novel, proprietary ingredients that are grounded in science and focused on enhancing health. We accept the award with enthusiasm and look forward to the exciting future that awaits pTeroPure.”
Frost & Sullivan benchmarked ChromaDex against key competitors across four criteria: unique selling features, continued research efforts, current market acceptance and growth potential, and marketing and promotion endeavors.
pTeroPure Pterostilbene is a naturally-occurring compound found in blueberries and belonging to a group of compounds called phytoalexins, which are produced by plants to fight infection from bacteria or fungi. Numerous published studies have shown that the compound has the ability to combat various health problems including diabetes, high blood pressure, high cholesterol, oxidative stress, and neurodegeneration.
“The highly beneficial properties of pterostilbene are expected to guarantee huge market potential for pterostilbene in the human nutrition industry,” said Sneha Pasricha, Frost & Sullivan senior research analyst.
ChromaDex has licensed two patents pending from the USDA through the University of Mississippi, a process patent from a manufacturing partner, and is filing a patent in collaboration with the University of California at Irvine. The two USDA patents focus on the ability of pterostilbene to reduce blood lipoprotein levels through PPAR-alpha activation and pterostilbene’s effect on oxidative stress and cognitive and memory enhancement, respectively. ChromaDex has a strategy to expand its patent portfolio related to pterostilbene with a number of additional filings.
The company is currently involved in an on-going clinical study with the University of Mississippi which will evaluate the effect of pterostilbene in patients with cholesterol and blood pressure problems.
“With such strengthening Intellectual Property body, pterostilbene is expected to expand into various health markets including anti-aging, heart health and memory enhancement,” said Pasricha.
About the Award
Frost & Sullivan’s awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
ChromaDex(TM) is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB)
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Investor Inquiries: Liviakis Financial Communications, Inc. John M. Liviakis, President 415-389-4670 John@Liviakis.com ChromaDex Contact Jenny Robles Administrative Assistant to the CEO and the President 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 949-419-0288 email@example.com Media Inquiries: Megan Lavine Canale Communications 4010 Goldfinch St., San Diego, CA, 92103 619-849-5388 firstname.lastname@example.org
SOURCE ChromaDex Corporation